S Hess1, G Baker2, G Gyenes3, R Tsuyuki3, S Newman1, Jean-Michel Le Melledo4,5. 1. Department of Psychiatry, University of Alberta, 114th street, Edmonton, AB, T6G 2B7, Canada. 2. Department of Psychiatry, Neurochemical Research Unit, University of Alberta, 114th street, Edmonton, AB, T6G 2B7, Canada. 3. Department of Cardiology, University of Alberta, 114th street, Edmonton, AB, T6G 2B7, Canada. 4. Department of Psychiatry, University of Alberta, 114th street, Edmonton, AB, T6G 2B7, Canada. jmlemelledo@gmail.com. 5. University of Alberta Hospital, 114th street, Edmonton, AB, T6G 2B7, Canada. jmlemelledo@gmail.com.
Abstract
RATIONALE: It has been suggested that endothelial dysfunction caused by a decreased endothelial production of nitric oxide (NO) may contribute to the consistently observed increased risk of developing cardiovascular disease (CVD) in physically healthy patients suffering from major depression (MD). NO is a gas synthesized from Larginine (a conditionally essential amino acid) and oxygen by endothelial nitric oxide synthase (eNOS). The end products of NO production include both NO and L-citrulline. NO is rapidly reduced to the anions nitrite and nitrate, classically referred to as NO metabolites. Their measurement has been used as a surrogate measurement for endothelial NO production. We and others have shown decreased levels of NO metabolites in the serum of MD patients. The mechanism of this decreased production of NO by the endothelium has not yet been elucidated. OBJECTIVES: The purpose of this study is to assess serum levels of L-arginine and L-citrulline in patients with MD. METHODS: Levels of L-arginine and L-citrulline were measured in 35 unmedicated physically healthy MD patients and 36 healthy controls (HCs). RESULTS: L-arginine and L-citrulline concentrations were significantly lower in MD patients than in healthy controls (L-arginine, 73.54 + 21.53 μmol/L and 84.89 + 25.16, p = 0.04 μmol/L and L-citrulline 31.58 + 6.05 μmol/L and 35.19 + 6.85 μmol/L, p = 0.03, respectively). CONCLUSIONS: The decrease in L-arginine levels in MD patients is a possible explanation for the decrease in NO metabolites in MD patients and therefore may contribute, through endothelial dysfunction, to the increased CV risk associated with MD.
RATIONALE: It has been suggested that endothelial dysfunction caused by a decreased endothelial production of nitric oxide (NO) may contribute to the consistently observed increased risk of developing cardiovascular disease (CVD) in physically healthy patients suffering from major depression (MD). NO is a gas synthesized from Larginine (a conditionally essential amino acid) and oxygen by endothelial nitric oxide synthase (eNOS). The end products of NO production include both NO and L-citrulline. NO is rapidly reduced to the anions nitrite and nitrate, classically referred to as NO metabolites. Their measurement has been used as a surrogate measurement for endothelial NO production. We and others have shown decreased levels of NO metabolites in the serum of MD patients. The mechanism of this decreased production of NO by the endothelium has not yet been elucidated. OBJECTIVES: The purpose of this study is to assess serum levels of L-arginine and L-citrulline in patients with MD. METHODS: Levels of L-arginine and L-citrulline were measured in 35 unmedicated physically healthy MD patients and 36 healthy controls (HCs). RESULTS:L-arginine and L-citrulline concentrations were significantly lower in MD patients than in healthy controls (L-arginine, 73.54 + 21.53 μmol/L and 84.89 + 25.16, p = 0.04 μmol/L and L-citrulline 31.58 + 6.05 μmol/L and 35.19 + 6.85 μmol/L, p = 0.03, respectively). CONCLUSIONS: The decrease in L-arginine levels in MD patients is a possible explanation for the decrease in NO metabolites in MD patients and therefore may contribute, through endothelial dysfunction, to the increased CV risk associated with MD.
Entities:
Keywords:
Cardiovascular risk; L-arginine; L-citrulline; Major depression; Nitric oxide
Authors: Rajat S Barua; John A Ambrose; Lesley-Jane Eales-Reynolds; Mary C DeVoe; John G Zervas; Dhanonjoy C Saha Journal: J Am Coll Cardiol Date: 2002-06-05 Impact factor: 24.094
Authors: Y Kamada; H Nagaretani; S Tamura; T Ohama; T Maruyama; H Hiraoka; S Yamashita; A Yamada; S Kiso; Y Inui; N Ito; Y Kayanoki; S Kawata; Y Matsuzawa Journal: J Clin Invest Date: 2001-09 Impact factor: 14.808
Authors: K B Holven; T Holm; P Aukrust; B Christensen; J Kjekshus; A K Andreassen; L Gullestad; T A Hagve; A Svilaas; L Ose; M S Nenseter Journal: Am J Med Date: 2001-05 Impact factor: 4.965
Authors: Juliano R Guerreiro; Claudiana Lameu; Eduardo F Oliveira; Clécio F Klitzke; Robson L Melo; Edlaine Linares; Ohara Augusto; Jay W Fox; Ivo Lebrun; Solange M T Serrano; Antonio C M Camargo Journal: J Biol Chem Date: 2009-06-02 Impact factor: 5.157
Authors: Louis T van Zyl; Francois Lespérance; Nancy Frasure-Smith; Alex I Malinin; Dan Atar; Marc-André Laliberté; Victor L Serebruany Journal: J Thromb Thrombolysis Date: 2008-01-11 Impact factor: 2.300
Authors: Christopher R Brydges; Sudeepa Bhattacharyya; Siamak Mahmoudian Dehkordi; Yuri Milaneschi; Brenda Penninx; Rick Jansen; Bruce S Kristal; Xianlin Han; Matthias Arnold; Gabi Kastenmüller; Mandakh Bekhbat; Helen S Mayberg; W Edward Craighead; A John Rush; Oliver Fiehn; Boadie W Dunlop; Rima Kaddurah-Daouk Journal: Brain Behav Immun Date: 2022-02-04 Impact factor: 19.227
Authors: Olga V Averina; Yana A Zorkina; Roman A Yunes; Alexey S Kovtun; Valeriya M Ushakova; Anna Y Morozova; George P Kostyuk; Valery N Danilenko; Vladimir P Chekhonin Journal: Int J Mol Sci Date: 2020-12-03 Impact factor: 5.923
Authors: Ahmed Ismaeel; Marco E Franco; Ramon Lavado; Evlampia Papoutsi; George P Casale; Matthew Fuglestad; Constance J Mietus; Gleb R Haynatzki; Robert S Smith; William T Bohannon; Ian Sawicki; Iraklis I Pipinos; Panagiotis Koutakis Journal: J Clin Med Date: 2019-09-14 Impact factor: 4.241